Browsing by Author "Raivio, Heini"

Immunopeptidomics research, focused on HLA-presented peptides, indicates that identifying neoantigens – unique peptides from cancer cell mutations – holds potential for personalized cancer treatment. PeptiCHIP, a compact microfluidic device from ValoTx, facilitates neoantigen identification in small tumor samples. This study evaluates PeptiCHIP against traditional immunopurification methods, assessing its advantages and commercial potential through stakeholder interviews guided by the double diamond model of design thinking. The aim is to establish PeptiCHIP’s unique advantages in immunopeptidomics research and precision oncology. Data for this research were gathered through semi-structured interviews and comparative laboratory analyses. The interviews revealed a positive reception among 19 stakeholders towards PeptiCHIP, highlighting a strong interest in its potential to accelerate workflows and enhance the personalization of cancer treatment. Laboratory comparisons confirmed that PeptiCHIP offers greater sensitivity than competitor products in detecting antigens, pinpointing the most immunogenic peptides from individual tumor samples. This suggests that the data could be effectively utilized as a targeted treatment approach in precision oncology therapies. The results indicate an eagerness to adopt PeptiCHIP, driven by its enhanced detection speed and accuracy. This research not only underscores the technological and commercial potential of PeptiCHIP in impacting precision oncology but also highlights the importance of aligning technological innovations with user needs and market demands. For ValoTx, a strategic commercial approach is needed to set a benchmark in precision oncology innovation.